Year To Quarter End Consolidated Statement Of Comprehensive Income

Daito Pharmaceutical Co., Ltd. - Filing #7569991

Concept 2022-06-01 to
2023-02-28
2021-06-01 to
2022-02-28
Year to quarter end consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
2,619,000,000 JPY
3,948,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
240,000,000 JPY
41,000,000 JPY
Foreign currency translation adjustment
0 JPY
74,000,000 JPY
Remeasurements of defined benefit plans, net of tax
58,000,000 JPY
4,000,000 JPY
Other comprehensive income
299,000,000 JPY
120,000,000 JPY
Comprehensive income
2,918,000,000 JPY
4,069,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
2,960,000,000 JPY
4,077,000,000 JPY
Comprehensive income attributable to non-controlling interests
-42,000,000 JPY
-7,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.